What question did this study set out to answer?

The aim is to evaluate the effectiveness of BCMA-specific CAR T cells in achieving remissions in patients with refractory or relapsed multiple myeloma.

May 20, 2017Journal of Clinical Oncology

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

View Full Paper

Ask AI

Bookmark

Authors

FFFrank FanChung Shan Medical University Hospital WZWanhong ZhaoMinistry of Education of the People's Republic of China JLJie LiuRutgers, The State University of New Jersey

Discussion

Member takes

Implication

Randomized trial demonstrates durable remissions in refractory multiple myeloma, suggesting effective treatment options.

Key Points

The aim is to evaluate the effectiveness of BCMA-specific CAR T cells in achieving remissions in patients with refractory or relapsed multiple myeloma.
Patients received BCMA-specific CAR-modified T cell therapy.
Assessment of remission duration and treatment efficacy in refractory multiple myeloma.
Follow-up evaluated the longevity of remissions.
Patients experienced significant improvements in remission rates.
Durability of remission was noted over an extended follow-up period.
Adverse effects were manageable and did not compromise treatment effectiveness.

Cite This Study

Fan et al. (2017) studied this question.

synapsesocial.com/papers/6a0f99ddb6f5ee04015fd678 https://doi.org/10.1200/jco.2017.35.15_suppl.lba3001

View Full Paper

Ask AI

Bookmark

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Discussion

Member takes

Implication

Key Points

Cite This Study

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider